Evidence map›Paper›PMID 28181292›Full record

ArticleEnvironmental and molecular mutagenesis2017

Tumor-associated APE1 variant exhibits reduced complementation efficiency but does not promote cancer cell phenotypes.

Jennifer L Illuzzi, Daniel R McNeill, Paul Bastian, Boris Brenerman, Robert Wersto, Helen R Russell, Fred Bunz, Peter J McKinnon, Kevin G Becker, David M Wilson

Open access · bronzeAbstract read
In one paragraph

Article in Environmental and molecular mutagenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Jennifer L IlluzziLaboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Daniel R McNeillLaboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Paul BastianLaboratory of Genetics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Boris BrenermanLaboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Robert WerstoFlow Cytometry Unit, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Helen R RussellGenetics Department, St. Jude Children's Research Hospital, Memphis, Tennessee.
Fred BunzDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Peter J McKinnonGenetics Department, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kevin G BeckerLaboratory of Genetics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
David M WilsonLaboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Institute on Aging · USNational Institute on Aging · USSt. Jude Children's Research Hospital · USNational Institutes of Health · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0M
Analysis of complex biological systems by microarray based gene expressionZICAG000616 · NIA · NATIONAL INSTITUTE ON AGING · PI DE, SUPRIYO · 2009 to 2025
$15.5M
Flow Cytometry Laboratory (Scientific Core)ZICAG000618 · NIA · NATIONAL INSTITUTE ON AGING · PI WENG, NAN-PING PETER · 2009 to 2025
$9.5M
ATM and DNA Damage in the Nervous SystemR01NS037956 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MCKINNON, PETER J · 1998 to 2022
$7.6M
Base Excision DNA Repair in Disease Susceptibility and TreatmentZIAAG000750 · NIA · NATIONAL INSTITUTE ON AGING · PI BOHR, VILHELM A · 2009 to 2019
$5.4M
Targeting the ATR pathway in p53-deficient cancersR01CA157535 · NCI · JOHNS HOPKINS UNIVERSITY · PI BUNZ, FRED · 2011 to 2015
$1.7M
A Genetic Model for Early-Onset Breast and Colon Cancer in African AmericansU01CA158428 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BUCKHAULTS, PHILLIP JOE, BUNZ, FRED · 2012 to 2016
$1.5M
ATM and DNA Damage in the Nervous SystemR56NS037956 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MCKINNON, PETER J · 2007 to 2007
$413k
Intramural NIH HHS ZIA AG000750NCI NIH HHS P01 CA096832NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA157535NCI NIH HHS U01 CA158428NINDS NIH HHS R01 NS037956NINDS NIH HHS R56 NS037956
6 · The paper itself

Abstract

Base excision repair (BER) is the major pathway for coping with most forms of endogenous DNA damage, and defects in the process have been associated with carcinogenesis. Apurinic/apyrimidinic endonuclease 1 (APE1) is a central participant in BER, functioning as a critical endonuclease in the processing of noncoding abasic sites in DNA. Evidence has suggested that APE1 missense mutants, as well as altered expression or localization of the protein, can contribute to disease manifestation. We report herein that the tumor-associated APE1 variant, R237C, shows reduced complementation efficiency of the methyl methanesulfonate hypersensitivity and impaired cell growth exhibited by APE1-deficient mouse embryonic fibroblasts. Overexpression of wild-type APE1 or the R237C variant in the nontransformed C127I mouse cell line had no effect on proliferation, cell cycle status, steady-state DNA damage levels, mitochondrial function, or cellular transformation. A human cell line heterozygous for an APE1 knockout allele had lower levels of endogenous APE1, increased cellular sensitivity to DNA-damaging agents, impaired proliferation with time, and a distinct global gene expression pattern consistent with a stress phenotype. Our results indicate that: (i) the tumor-associated R237C variant is a possible susceptibility factor, but not likely a driver of cancer cell phenotypes, (ii) overexpression of APE1 does not readily promote cellular transformation, and (iii) haploinsufficiency at the APE1 locus can have profound cellular consequences, consistent with BER playing a critical role in proliferating cells. Environ. Mol. Mutagen. 58:84-98, 2017. © 2017 Wiley Periodicals, Inc.

Indexed as

AnimalsCell CycleCell ProliferationCell SurvivalCell Transformation, NeoplasticDNA-(Apurinic or Apyrimidinic Site) LyaseDNA DamageDNA RepairFibroblastsGene Knockout TechniquesGenetic Complementation TestHCT116 CellsHumansMesylatesMice, TransgenicTamoxifenAPEX1 protein, humanApex1 protein, mouseDNA-(Apurinic or Apyrimidinic Site) LyaseMesylatesmethanesulfonic acidTamoxifenAPE1/APEX1base excision repaircancer susceptibilityhaploinsufficiencytransformation

Identifiers

PMID28181292
PMCPMC5321783
OpenAlexW2586273188

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.